Reuters logo
BRIEF-Resverlogix reports $87 mln private placement with Shenzhen Hepalink
October 13, 2017 / 1:38 PM / a month ago

BRIEF-Resverlogix reports $87 mln private placement with Shenzhen Hepalink

Oct 13 (Reuters) - Resverlogix Corp:

* Resverlogix announces $87 million private placement with shenzhen hepalink

* Resverlogix Corp - ‍net proceeds of offering will primarily be used to repay company’s $68.8 million secured loan which matures on December 26, 2017​

* Resverlogix Corp - ‍ private placement of 60.4 million equity units to Shenzhen Hepalink Pharmaceutical Co. Ltd. At a price of $1.44 per unit​

* Resverlogix-Proceeds will also be used to fund research,development activities for clinical trial activities related to phase 3 betonmace trial​

* Resverlogix - ‍ placement to address co’s financial difficulties by providing sufficient funds to repay loan and to satisfy short term cash requirements​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below